<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Checkpoint Therapeutics, Inc.

    Checkpoint Therapeutics, Inc.

    Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncol...

    Checkpoint Therapeutics, Inc. (“Checkpoint”...

    Filing Type:    PU
    Crooru Corporation

    Crooru Corporation

    crooru is an on-demand, location-based app that connects health care staff and nur...

    crooru is an on-demand, location-based app that...

    Amount Raised:    $15,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Ascendis Pharma A/S

    Ascendis Pharma A/S

    Ascendis Pharma is applying its innovative technology platform to build a leading,...

    Ascendis Pharma is applying its innovative tech...

    Filing Type:    PU
    argenx SE

    argenx SE

    argenx is a clinical-stage biotechnology company developing a deep pipeline of dif...

    argenx is a clinical-stage biotechnology compan...

    Filing Type:    PU
    Adaptive Biotechnologies Corporation

    Adaptive Biotechnologies Corporation

    We are a commercial-stage biotech company focused on harnessing the inherent biolo...

    We are a commercial-stage biotech company focus...

    Filing Type:    PU
    Royal Philips NV

    Royal Philips NV

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focuse...

    Royal Philips (NYSE: PHG, AEX: PHIA) is a leadi...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Marker Therapeutics, Inc.

    Marker Therapeutics, Inc.

    We are a clinical-stage immuno-oncology company specializing in the development an...

    We are a clinical-stage immuno-oncology company...

    Filing Type:    PU
    Nektar Therapeutics

    Nektar Therapeutics

    Nektar Therapeutics is a research-based development stage biopharmaceutical compan...

    Nektar Therapeutics is a research-based develop...

    Filing Type:    PU
    ViewRay, Inc.

    ViewRay, Inc.

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...

    Filing Type:    PU
    Regeneron Pharmaceuticals, Inc.

    Regeneron Pharmaceuticals, Inc.

    We are a leading science and technology company that delivers life-transforming me...

    We are a leading science and technology company...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.